Loading...
XSHE000790
Market cap338mUSD
Jan 02, Last price  
3.96CNY
1D
1.54%
1Q
-1.49%
Jan 2017
-57.00%
Name

Chengdu Huasun Technology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:000790 chart
P/E
89.30
P/S
2.46
EPS
0.04
Div Yield, %
0.25%
Shrs. gr., 5y
2.34%
Rev. gr., 5y
9.64%
Revenues
1.00b
+14.92%
193,800,179187,758,119223,849,032275,663,873363,187,884380,877,510489,033,441551,511,666580,530,915657,809,857528,216,541463,311,851575,194,221590,948,888633,417,693745,340,799759,307,481954,939,781873,103,0221,003,376,636
Net income
28m
-32.89%
1,360,8812,214,5925,401,0621,845,6995,109,2607,204,70712,479,65320,841,54333,671,31850,062,29466,093,057082,497,356171,667,02131,169,35261,632,30237,503,53155,634,83241,217,51827,659,463
CFO
47m
-69.58%
12,422,06722,353,85118,561,9842,107,33912,003,34729,603,131116,005,68759,965,333034,850,0550051,590,6270107,736,44365,027,23813,495,8000155,887,75147,414,104
Dividend
Jul 26, 20240.01 CNY/sh
Earnings
May 29, 2025

Profile

Chengdu Huasun Technology Group Inc., Ltd. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, traditional Chinese medicines, and chemical medicines; and sells drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu Huasun Technology Group Inc., Ltd. in April 2020. Chengdu Huasun Technology Group Inc., Ltd. was founded in 1998 and is based in Chengdu, China.
URL
http://www.huasungrp.com/
IPO date
Mar 27, 1998
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,003,377
14.92%
873,103
-8.57%
Cost of revenue
856,248
754,943
Unusual Expense (Income)
NOPBT
147,128
118,160
NOPBT Margin
14.66%
13.53%
Operating Taxes
(329)
7,842
Tax Rate
6.64%
NOPAT
147,458
110,318
Net income
27,659
-32.89%
41,218
-25.91%
Dividends
(6,281)
(6,256)
Dividend yield
0.18%
0.22%
Proceeds from repurchase of equity
(1,638)
(1)
BB yield
0.05%
0.00%
Debt
Debt current
276,353
91,441
Long-term debt
32,710
117,547
Deferred revenue
2,438
3,520
Other long-term liabilities
69,236
14,915
Net debt
(128,848)
(260,442)
Cash flow
Cash from operating activities
47,414
155,888
CAPEX
(189,308)
Cash from investing activities
(243,105)
Cash from financing activities
274,724
85,854
FCF
34,696
102,240
Balance
Cash
211,180
144,638
Long term investments
226,732
324,792
Excess cash
387,743
425,775
Stockholders' equity
881,632
950,754
Invested Capital
1,053,033
720,929
ROIC
16.62%
15.99%
ROCE
10.10%
10.26%
EV
Common stock shares outstanding
691,487
618,538
Price
5.06
11.21%
4.55
-28.46%
Market cap
3,498,922
24.32%
2,814,349
-28.21%
EV
3,539,629
2,556,326
EBITDA
181,845
152,365
EV/EBITDA
19.47
16.78
Interest
9,949
4,280
Interest/NOPBT
6.76%
3.62%